We are excited for the significant growth opportunities in front of Clear Labs, and Ed’s appointment underscores our commitment to bringing on the best and brightest minds in our field.
SAN CARLOS, Calif. (PRWEB) July 11, 2022
Today, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, announced the appointment of Edward Fan as its new Chief Financial Officer to support the company’s next phase of growth. Fan joins Clear Labs following a distinguished career in healthcare investment banking at J.P. Morgan and Lazard and a range of operating roles at leading healthcare companies.
“Ed is an accomplished business leader and brings a significant and unique blend of experience spanning the investment banking, clinical diagnostics, biotech and pharma industries,” said Sasan Amini, co-founder and CEO of Clear Labs. “We are excited for the significant growth opportunities in front of Clear Labs, and Ed’s appointment underscores our commitment to bringing on the best and brightest minds in our field. In addition to his extensive experience, he brings the passion, vision and energy that can help us get to the next level as we address a growing market need for turnkey genomics solutions.”
Most recently, Fan served as an Executive Director in J.P. Morgan’s Healthcare Investment Banking team, where he advised Life Sciences Tools and Diagnostics companies on IPOs, M&A, and other financial activities. He began his investment banking career at Lazard, where he was a Vice President and advised healthcare companies on M&A and other strategic matters. Earlier in his career, Fan held operating roles at Sanofi, Werfen, and Shire Pharmaceuticals in marketing, product management, competitive intelligence, and R&D, and he also provided consulting services to in vitro diagnostics companies at Boston Biomedical Consultants.
“I’m thrilled to be joining the Clear Labs team and excited by our mission and opportunity to deliver our capabilities to more public health organizations, reference labs, hospitals and epidemiologists worldwide,” said Fan. “This is a remarkable time to be in genomics, and the power of NGS has never been clearer. The Clear Labs technology and platform is both proven and unparalleled and will undoubtedly make an impact on the future of diagnostics and healthcare. I’m humbled and excited to be part of Clear Labs’ incredible journey.”
Clear Labs has seen a dramatic increase in demand for its platform and is being used by more than half of all state U.S. public health laboratories for pathogen surveillance. In addition to its clinical solutions, Clear Labs is a pioneer in food safety for Listeria and Salmonella detection through its Clear Safety platform. For more information about Clear Labs and all of its offerings, visit https://www.clearlabs.com/.
About Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex workflows for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs liberates genomics to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy for detection and surveillance of infectious diseases. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.